Astellas Sees Turnaround With Urology, Transplantation And Oncology Products
This article was originally published in PharmAsia News
Executive Summary
Astellas has rolled out a five-year management plan to bounce back from patent expiries and declining sales; and fresh off a long-fought bid for OSI Pharmaceuticals, the company expects oncology to bolster growth driven by its core therapeutic competencies of urology and transplantation
You may also be interested in...
Astellas Completes OSI Acquisition; Shares Jump In Tokyo
Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding
Astellas Completes OSI Acquisition; Shares Jump In Tokyo
Astellas announced the completion of its acquisition of OSI Pharmaceuticals, obtaining 93 percent of OSI Pharmaceuticals' publicly traded shares. The New York-based company immediately became a wholly owned subsidiary of Astellas U.S. Holding
Astellas Wins OSI But Victory Comes At A Price
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17, 2010 with a definitive merger agreement that has the unanimous support of both companies' boards. The victory cost $4 billion, about $500 million more than the original hostile bid which Astellas launched in late February ("The Pink Sheet" DAILY, March 1, 2010)